title: Effect of pretransplant hemoglobin blood level on kidney transplant outcome.
abstract: OBJECTIVE
  We investigated the effect of pretransplant hemoglobin level on the outcome of kidney transplant.
  
  
  METHODS
  Patients were divided in 2 groups: group A < 10 g/dL (80 patients; PTHb < 10 g/dL), and group B > 10 g/dL (69 patients; PTHb = 10 g/dL), and were matched regarding donor age, recipient sex, blood group, donor recipient HLA, and Cytomegalovirus status.
  
  
  RESULTS
  The frequency of acute rejection, together with the timing of rejection, the need for antithymocyte globulin Fresenius rescue therapy, infection rate, and posttransplant surgical complications were comparable between both groups. While the 1-year actuarial patient and graft survival rates, delayed graft function, and slow graft function rates were comparable between both groups, longer hospital stay was required for group B (> 10 g/dL) patients (P = .005). Mean serum creatinine levels upon discharge (P = .02), at 6 months (P = .05), and 1 year (P = .02) after discharge were higher in group B (> 10 g/dL) patients. While posttransplant hemoglobin levels were lower than pretransplant levels, they were higher in group B (> 10 g/dL) compared with group A (< 10 g/dL), (P = .019).
  
  
  CONCLUSIONS
  Pretransplant hemoglobin level does not affect the outcome of kidney transplant, except for creatinine levels at 1 year.
authors.affiliation: Department of Surgery, Sacre-Coeur Hospital, Baabda-Hazmieh, Lebanon.
authors.forename: Maroun M
authors.initials: MM
authors.lastname: Abou-Jaoude
authors.forename: Naji
authors.initials: N
authors.lastname: Nawfal
authors.forename: Robert
authors.initials: R
authors.lastname: Najm
authors.forename: Joseph
authors.initials: J
authors.lastname: Shaheen
authors.forename: Wassim Y
authors.initials: WY
authors.lastname: Almawi
mesh_terms: D000208:Acute Disease; D000328:Adult; D000740:Anemia / Q000097:blood / Q000150:complications* / Q000628:therapy; D015415:Biomarkers / Q000097:blood; D003141:Communicable Diseases / Q000097:blood / Q000209:etiology; D003404:Creatinine / Q000097:blood; D051799:Delayed Graft Function / Q000097:blood / Q000209:etiology; D004359:Drug Therapy, Combination; D017707:Erythrocyte Transfusion; D005260:Female; D006084:Graft Rejection / Q000097:blood / Q000209:etiology; D006085:Graft Survival; D006397:Hematinics / Q000627:therapeutic use; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects / Q000401:mortality; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D011300:Preoperative Care; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D006397:Hematinics; D006454:Hemoglobins; D007166:Immunosuppressive Agents; D003404:Creatinine